Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2 Completed 267 enrolled AbbVie

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test if the investigational medication, ABT-384, is a safe and effective treatment for adults with mild-to-moderate Alzheimer's Disease.

Timeline

Start: 2010-05
Primary completion: 2011-07
Completion: 2011-07

Outcome

Missed primary endpoint

paper ABT-384 did not improve ADAS-Cog scores or any secondary end point PMID 24418055 ↗

Publications

Marek GJ, Katz DA, Meier A, Greco N 4th, Zhang W, Liu W, Lenz RA. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dement. 2014 Oct;10(5 Suppl):S364-73. doi: 10.1016/j.jalz.2013.09.010. Epub 2014 Jan 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-384	Small molecule	10 mg	—
Subject	ABT-384	Small molecule	50 mg	—
Comparator	Donepezil	Small molecule	10 mg	—